Cargando…
N(ɛ)-acetyl lysine derivatives with zinc binding groups as novel HDAC inhibitors
HDAC inhibitors have been developed very rapidly in clinical trials and even in approvals for treating several cancers. However, there are few reported HDAC inhibitors designed from N(ɛ)-acetyl lysine. In the current study, we raised a novel design, which concerns N(ɛ)-acetyl lysine derivatives cont...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Royal Society
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6599804/ https://www.ncbi.nlm.nih.gov/pubmed/31312496 http://dx.doi.org/10.1098/rsos.190338 |